Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna's financial outlook remains robust, with projected product sales increasing from $1.73 billion in 2025 to $2.15 billion in 2026, driven by a diverse pipeline of 35 mRNA development candidates targeting various therapeutic areas. The company bolstered its financial flexibility through a $1.5 billion debt deal and improved manufacturing efficiency, which is expected to enhance gross margins from 30% in 2023 back to 50% in 2025 and potentially expand by an additional 10% over the next three years. Additionally, positive clinical trial results for key programs, including immunotherapies and the mRNA-3927 for propionic acidemia, further establish the potential for long-term revenue growth and sustained market presence.

Bears say

The financial outlook for Moderna's stock appears negative due to a significant decline in COVID vaccine sales, which fell from $18 billion in 2022 to $6.7 billion in 2023, with further reductions in guidance for 2025 amid waning vaccination rates. Additional concerns stem from competition in the respiratory vaccines market and a slow pipeline progress for other therapeutic areas, impacting overall revenue growth potential. Furthermore, projections for COVID-related sales are estimated to decrease substantially from $3.5 billion to $2.5 billion annually as the pandemic transitions to an endemic phase, alongside expectations of low sales in the EU market for 2024 and likely 2025.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.